Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease
Abstract
Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open the blood-brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than in the homologous regions in the contralateral hemisphere that were not treated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of 30 to 180 days after treatment. (Funded by the Harry T. Mangurian, Jr. Foundation and the West Virginia University Rockefeller Neuroscience Institute.).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound.
Rezai, A. R., Ranjan, M., D’Haese, P.-F., Haut, M. W., Carpenter, J., Najib, U., Mehta, R. I., Chazen, J. L., Zibly, Z., Yates, J. R., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002571117 · Cited by 365 · see citing works
Self-citationKrishna, V., Sammartino, F., & Rezai, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3129 · Cited by 289 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer’s disease drug development pipeline: 2024
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12465 · Cited by 702 · see citing works
- Authors
- Rezai, A. R., D’Haese, P.-F., Finomore, V., Carpenter, J., Ranjan, M., Wilhelmsen, K., Mehta, R. I., Wang, P., Najib, U., Vieira Ligo Teixeira, C., Arsiwala, T., Tarabishy, A., Tirumalai, P., Claassen, D. O., Hodder, S., & Haut, M. W.
- Affiliations
- From the Departments of Neurosurgery (A.R.R., P.-F.D., M.R.), Neuroradiology (P.-F.D., J.C., R.I.M., P.W., A.T.), Neuroscience (A.R.R., V.F., C.V.L.T., T.A., P.T., M.W.H., R.I.M.), Neurology (K.W., U.N., M.W.H.), and Behavioral Medicine and Psychiatry (M.W.H.), Rockefeller Neuroscience Institute, Department of Medicine (S.H.), and West Virginia Clinical and Translational Science Institute (S.H.), West Virginia University, Morgantown; and the Department of Neurology, Vanderbilt University, Nashville (D.O.C.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-04
- Volume
- 390
- Issue
- 1
- Pages
- 55-62
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4390547811
- Cited by
- 312
- References
- 3
- Citations by year
- 2026: 103 · 2025: 139 · 2024: 70
- FWCI
- 80.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- The Harry T. Mangurian, Jr. Foundation
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- Alzheimer's disease, aducanumab, focused ultrasound, blood-brain barrier opening, cerebral amyloid-beta, cognitive outcomes, drug safety
- MeSH terms
- Alzheimer Disease, Blood-Brain Barrier, Brain, Humans, Ultrasonic Therapy, Amyloid beta-Peptides, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
